{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:05:29Z","timestamp":1789427129180,"version":"build-2803163510"},"reference-count":24,"publisher":"Georg Thieme Verlag KG","issue":"09","funder":[{"DOI":"10.13039\/501100007062","name":"Yangzhou University","doi-asserted-by":"crossref","award":["XCX20250938"],"award-info":[{"award-number":["XCX20250938"]}],"id":[{"id":"10.13039\/501100007062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This meta-analysis aimed to clarify the association between glucagon-like peptide-1 receptor agonists, used for weight management in obesity, and the risks of pancreatitis and pancreatic cancer. We systematically searched PubMed, Web of Science, Embase, the Cochrane Library, and Scopus through June 15, 2026, for clinical studies conducted in obese populations. Peto odds ratios with 95% confidence intervals were calculated. Heterogeneity was assessed using I\u00b2 statistic, and random-effects models were applied when I\u00b2 exceeded 60%. Subgroup analyses were conducted according to study design, follow-up duration, control type, glucagon-like peptide-1 receptor agonist agent type, and dose regimen. Leave-one-out sensitivity analyses were additionally performed. This meta-analysis included 52 studies. The pooled analysis demonstrated no significant association between glucagon-like peptide-1 receptor agonist use and pancreatic cancer (odds ratio=1.34; 95% confidence interval: 0.76\u20132.34; p=0.31) or pancreatitis (odds ratio=1.29; 95% confidence interval: 0.91\u20131.84; p&gt;0.05). Additional subgroup analyses according to study design, follow-up duration, control type, and dose regimen yielded findings consistent with the primary analyses. Leave-one-out sensitivity analyses were performed to assess the robustness of the pooled estimates. Glucagon-like peptide-1 receptor agonists used for weight management in obesity were not associated with an increased risk of pancreatitis or pancreatic cancer. The consistency of findings across multiple subgroup and sensitivity analyses further supports the pancreatic safety profile of glucagon-like peptide-1 receptor agonists.<\/jats:p>","DOI":"10.1055\/a-2923-3830","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T22:52:08Z","timestamp":1786747928000},"page":"354-363","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Glucagon-Like Peptide-1 Receptor Agonists as Weight Loss Drugs on Pancreatitis and Pancreatic Cancer: A Meta-Analysis"],"prefix":"10.1055","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1406-7597","authenticated-orcid":false,"given":"Xinai","family":"Zhong","sequence":"first","affiliation":[{"name":"Yangzhou University, Jiangsu, China","place":["Yangzhou"],"department":["School of Nursing, Faculty of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqi","family":"Zhao","sequence":"first","affiliation":[{"name":"Xinghua People\u2019s Hospital Affiliated to Yangzhou University, Jiangsu, China","place":["Taizhou"],"department":["Nursing Department"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Han","sequence":"additional","affiliation":[{"name":"Yangzhou University, Jiangsu, China","place":["Yangzhou"],"department":["School of Nursing, Faculty of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Zheng","sequence":"additional","affiliation":[{"name":"Yangzhou University, Jiangsu, China","place":["Yangzhou"],"department":["School of Nursing, Faculty of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Cheng","sequence":"additional","affiliation":[{"name":"Yangzhou University, Jiangsu, China","place":["Yangzhou"],"department":["School of Nursing, Faculty of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beixi","family":"Shi","sequence":"additional","affiliation":[{"name":"Yangzhou University, Jiangsu, China","place":["Yangzhou"],"department":["School of Nursing, Faculty of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Yangzhou University, Jiangsu, China","place":["Yangzhou"],"department":["School of Nursing, Faculty of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"A Afshin","year":"2017","journal-title":"N Engl J Med"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ajg.2012.381","article-title":"Abdominal and total adiposity and the risk of acute pancreatitis: A population based prospective cohort study","volume":"108","author":"O Sadr Azodi","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"09","key":"ref3","doi-asserted-by":"crossref","first-page":"djx012","DOI":"10.1093\/jnci\/djx012","article-title":"The role of obesity, type 2 diabetes, and metabolic factors in pancreatic cancer: A mendelian randomization study","volume":"109","author":"R Carreras Torres","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP 1 receptor agonists: Beyond their pancreatic effects","volume":"12","author":"X Zhao","year":"2021","journal-title":"Front Endocrinol Lausanne"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once weekly semaglutide in adults with overweight or obesity","volume":"384","author":"JP H Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1172\/JCI97233","article-title":"Discovery, characterization, and clinical development of the glucagon like peptides","volume":"127","author":"D J Drucker","year":"2017","journal-title":"J Clin Invest"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s43440-024-00629-x","article-title":"A review of serious adverse events linked with GLP 1 agonists in type 2 diabetes mellitus and obesity treatment","volume":"76","author":"M Tobaiqy","year":"2024","journal-title":"Pharmacol Rep"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.14309\/ajg.0000000000003525","article-title":"Glucagon like peptide 1 receptor agonists use does not increase the risk for acute pancreatitis and is associated with lower complications in patients with type 2 diabetes who develop acute pancreatitis: A multicenter analysis","volume":"121","author":"L M Nieto","year":"2026","journal-title":"Am J Gastroenterol"},{"issue":"09","key":"ref9","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/dom.12926","article-title":"Safety issues with glucagon like peptide 1 receptor agonists pancreatitis, pancreatic cancer and cholelithiasis: Data from randomized controlled trials","volume":"19","author":"M Monami","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"e70013","DOI":"10.1111\/1753-0407.70013","article-title":"The potential adverse effects of hypodermic glucagon like peptide 1 receptor agonist on patients with type 2 diabetes: A population based study","volume":"16","author":"Z Cheng","year":"2024","journal-title":"J Diabetes"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/gutjnl-2024-334591","article-title":"Glucagon like peptide 1 receptor agonist use is associated with a lower risk of major adverse liver related outcomes: A meta analysis of observational cohort studies","volume":"74","author":"C Celsa","year":"2025","journal-title":"Gut"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/annonc\/mdv392","article-title":"Statistical controversies in clinical research: Long term follow up of clinical trials in cancer","volume":"26","author":"J Cuzick","year":"2015","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990 to 2017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP 1 medicines for type 2 diabetes and obesity","volume":"47","author":"D J Drucker","year":"2024","journal-title":"Diabetes Care"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00125-009-1515-4","article-title":"Biochemical and histological effects of exendin 4 exenatide on the rat pancreas","volume":"53","author":"J S Nachnani","year":"2010","journal-title":"Diabetologia"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/s41598-019-38956-2","article-title":"Glucagon like peptide 1 receptor agonists and pancreatic cancer: A meta analysis with trial sequential analysis","volume":"9","author":"L C Pinto","year":"2019","journal-title":"Sci Rep"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP 1 and GIP","volume":"132","author":"L L Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2337\/db14-0883","article-title":"Glucagon like peptide 1 receptor agonists increase pancreatic mass by induction of protein synthesis","volume":"64","author":"J A Koehler","year":"2015","journal-title":"Diabetes"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"E1431","DOI":"10.1152\/ajpendo.00017.2014","article-title":"Activation of glucagon like peptide 1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP dependent manner","volume":"306","author":"H Zhao","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"08","key":"ref20","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00125-017-4289-0","article-title":"Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: A randomised, double blind, placebo controlled trial","volume":"60","author":"C Kapitza","year":"2017","journal-title":"Diabetologia"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jnci\/89.6.442","article-title":"Hereditary pancreatitis and the risk of pancreatic cancer","volume":"89","author":"A B Lowenfels","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MPA.0000000000000521","article-title":"Glucagon like peptide 1 receptor expression in normal and neoplastic human pancreatic tissues","volume":"45","author":"M Dal Molin","year":"2016","journal-title":"Pancreas"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon like peptide 1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Z Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon like peptide 1 receptor activation inhibits Toll like receptor agonist induced inflammation","volume":"36","author":"C K Wong","year":"2024","journal-title":"Cell Metab"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2923-3830.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:41:32Z","timestamp":1789425692000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2923-3830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":24,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2026,9,14]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2923-3830","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}